There is one clinical trial.
The primary objective of this study is determine the safety and efficacy of ACT-20-MSC (allogenic human umbilical derived mesenchymal stem cells) and ACT-20-CM (allogenic human umbilical derived mesenchymal stem cells in conditioned media) in patients with moderate to severe COVID-19 pneumonia.
Description: Number of ventilator-free days
Measure: Ventilated Subjects - Ventilator Free Days Time: 28 days post treatmentDescription: Improvement in ventilator settings: Minute ventilation, PEEP, FiO2
Measure: Ventilated Subjects - Improvement in Ventilator Settings Time: 28 days post treatment, or until off of ventilatorDescription: Days of step-down O2 therapy as evidenced by: improvement in required volume, change to nasal cannula or face mask delivery or improvement in required concentration.
Measure: High-Flow O2 Support Subjects - Step-Down O2 Therapy Time: 30 days post treatment, or until off of high-flow O2 supportDescription: Respiration Rate < 30 for > 24 hours.
Measure: High Flow O2 Support Subjects - Respiration Rate Time: 30 days post treatment, or until off of high-flow O2 supportDescription: Number of ICU-free days
Measure: Both Ventilated and High-Flow O2 Support Subjects - ICU-Free Days Time: 30 days post treatment, or until off of ventilator or high-flow O2 supportDescription: Improvement in pulmonary function as evidenced by A-A oxygen gradient, O2 saturation
Measure: Both Ventilated and High-Flow O2 Support Subjects - Pulmonary Function Improvement Time: 30 days post treatment, or until off of ventilator or high-flow O2 supportDescription: Increased Berlin Criteria score > 24 hours
Measure: Both Ventilated and High-Flow O2 Support Subjects - Increased Berlin Score Time: 30 days post treatment, or until off of ventilator or high-flow O2 support